Bexarotene

来源:http://www.songofegypt.net 作者:历史 人气:55 发布时间:2019-04-16
摘要:IGCP567地震考古研究项目最新动态消息 "目录号: HY-14171 欢迎有对于地震考古研究和喇家遗址史前地震感兴趣的年轻朋友及时与我们联系 MetabolicEnzyme/Protease Autophagy -   Bexarotene (Targretin)是

IGCP567地震考古研究项目最新动态消息

"目录号: HY-14171

欢迎有对于地震考古研究和喇家遗址史前地震感兴趣的年轻朋友及时与我们联系

Metabolic Enzyme/ProteaseAutophagy-

 

Bexarotene (Targretin)是维甲酸X受体(RXR)激动剂,可作用于CTCL。

 

RAR/RXRAutophagy

MEETINGS

相关产品

· On 22 February 2012 IGCP will celebrate its 40th Anniversary at the UNESCO Headquarters in Paris. Two of our co-leaders will actively participate at this meeting. Iain Stewart (University of Plymouth, U.K.) will focus on the importance of Geosciences for Society and moderate a debate on the prospective vision for the future of IGCP. Manuel Sintubin (Katholieke Universiteit Leuven, Belgium) will reflect on the role of IGCP in geohazard mitigation based on the success of IGCP567.

Cycloheximide-TAK-242-LY294002-3-Methyladenine-( )-JQ-1-SB 203580-SP600125-U0126-Enzalutamide-Actinomycin D-Olaparib-Doxorubicin hydrochloride-Dorsomorphin dihydrochloride-Mitomycin C-Bortezomib-

 

生物活性

·At the 2012 Annual Meeting of the Seismological Society of America (17-19 April, 2012, San Diego, California): Earthquakes and Tsunamis at Caostal Archaeological Sites. You find details in the following announcement (pdf ). Abstract submission deadline is 11 January 2012.

Description

 

Bexarotene (Targretin) is a selective RXR agonist approved for the treatment of CTCL.IC50 value:Target: retinoid X receptorExposure of NSCLC cell lines to bexarotene as a single agent had modest growth inhibitory effects (at > 1 μM). However, exposure of several NSCLC lines to bexarotene (1–3 μM) produced significant decreases in the expression of EGFR, Her-2 and TGF mRNA and protein. EGF levels were also decreased to a much lesser degree.

·At the 34th International Geological Congress (IGC), from 2 to 10 August 2012 at Brisbane, Queensland, Australia a special session is convened by Patrick Nunn (Australia), Bruce McFadgen (New Zealand), Iain Stewart (U.K.) and Manuel Sintubin (Belgium) on Natural Hazards and Ancient Societies. Abstract submission deadline is 17 February 2012.

Clinical Trial

 

NCT00153842

·In November 2012 we are furthermore planning an international workshop Shakin’ them off? Interdisciplinary perspectives on Minoan Earthquakes, convened by Simon Jusseret (Université Catholique de Louvain, Belgium) and Manuel Sintubin (Katholieke Universiteit Leuven, Belgium), which will take place in Leuven (Belgium).

Dartmouth-Hitchcock Medical Center-Bristol-Myers Squibb-Ligand Pharmaceuticals

 

Carcinoma, Non-small-cell Lung

For both conferences IGCP567 will most probably (depending on our funding) be able to offer travel grants.

August 2001

 

Phase 1-Phase 2

·At the EGU meeting (20-24 April 2012, Vienna, Austria) Matthieu Ferry (Géosciences Montpellier, France) and Kris Vanneste (ROB, Belgium) convene a session on Earthquake Geology. Abstract submission deadline is 17 January 2012.

NCT00615784

 

Abramson Cancer Center of the University of Pennsylvania

·The 3rd Workshop on Paleoseismology and Archaeoseismology will be held in Morelia, Mexico from 1 to 8 November 2012. More information will follow soon on the http://www.acambay1912.org.

Acute Myeloid Leukemia

 

January 2008

PUBLICATIONS

Phase 2

 

NCT01504490

Following our 2nd INQUA-IGCP567 International Workshop on Active Tectonics, Earthquake Geology, Archaeology and Engineering, held from 18 to 24 September 2011 in Corinth, Greece, Andreas Vött (University of Mainz, Germany) is preparing a special volume on in the Zeitschrift für Geomorphologie. This is a peer-review ISI-indexed journal and hosted up to now three special volumes on tsunamis. If you are interested to contribute to this volume, please contact Andreas Vött (voett@uni-mainz.de).

Georgetown University-Daiichi Sankyo Inc.

 

Solid Tumors-Lymphoma-Multiple Myeloma

International Geoscience Programme
IGCP 567 Earthquake Archaeology

December 2011

De wetenschap van de Aarde. Over een levende planeet

Phase 1


NCT00125372

 

Dartmouth-Hitchcock Medical Center-Ligand Pharmaceuticals-Genentech, Inc.

Disclaimer: http://www.kuleuven.be/cwis/email_disclaimer.htm

Carcinoma, Non-small-cell Lung

December 2005

NCT00845351

University of Virginia

Cushing's Disease

November 2008

Phase 1-Phase 2

NCT01782742

The Cleveland Clinic

Alzheimer's Disease

February 2013

Phase 2

NCT01116622

Dartmouth-Hitchcock Medical Center-Genentech, Inc.-Ligand Pharmaceuticals

Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and Esophagus)

April 2003

Phase 1

NCT00055991

Baylor Breast Care Center-National Cancer Institute (NCI)

Breast Cancer

September 2001

Phase 1

NCT00125359

Dartmouth-Hitchcock Medical Center-Ligand Pharmaceuticals-Genentech, Inc.

Carcinoma, Non-small-cell Lung

August 2005

Phase 2

NCT02061878

ReXceptor, Inc.

Alzheimer's Disease

August 2014

Phase 1

NCT01007448

Valeant Pharmaceuticals International, Inc.

Refractory Cutaneous T-cell Lymphoma

December 2009

Phase 4

NCT00660231

University College, London

Lymphoma

March 2008

Phase 2

NCT01001143

Washington University School of Medicine

Leukemia, Myeloid, Acute

May 2010

Phase 1

NCT00316030

Abramson Cancer Center of the University of Pennsylvania

AML-Acute Myeloid Leukemia

January 2004

Phase 1

NCT00411632

M.D. Anderson Cancer Center-United States Department of Defense

Lung Cancer

November 2006

Phase 2

NCT00306969

Boston University-Ligand Pharmaceuticals

Cutaneous T-Cell Lymphoma

December 2001

Phase 1-Phase 2

NCT00535574

Beersheva Mental Health Center

Schizophrenia

November 2008

Phase 3

NCT01578499

Millennium Pharmaceuticals, Inc.-Seattle Genetics, Inc.-Takeda

Primary Cutaneous Anaplastic Large Cell Lymphoma-Mycosis Fungoides-Cutaneous T-Cell Lymphoma

August 2012

Phase 3

NCT00255801

Memorial Sloan Kettering Cancer Center-National Cancer Institute (NCI)-Tibotec Pharmaceutical Limited-M.D. Anderson Cancer Center-New York University School of Medicine-Hackensack University Medical Center-Roswell Park Cancer Institute

Lymphoma

November 2005

Phase 2

NCT00178841

Vanderbilt University

Cutaneous T-cell Lymphoma-Mycosis Fungoides-Sezary Syndrome

June 2005

Phase 2

NCT00141947

Beersheva Mental Health Center-Stanley Medical Research Institute

Schizophrenia

September 2005

Phase 3

NCT00151008

University of Medicine and Dentistry of New Jersey-Ligand Pharmaceuticals-Rutgers, The State University of New Jersey

Psoriasis

November 2003

Phase 2

NCT01134341

Spectrum Pharmaceuticals, Inc

Cutaneous T-cell Lymphoma-Mycosis Fungoides-Sezary Syndrome-Primary Cutaneous Anaplastic Large Cell Lymphoma

March 2010

本文由美高梅在线登录网址发布于历史,转载请注明出处:Bexarotene

关键词:

最火资讯